Selank

Overview

Selank is a synthetic heptapeptide developed as a stabilized analog of the endogenous immunomodulatory peptide tuftsin. The addition of a C-terminal Pro-Gly-Pro extension confers resistance to enzymatic degradation. Selank has been studied in preclinical models for its role in anxiolytic pathway research and immune system signaling (Zozulya et al., 2008 — PMID: 18622260).

History

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s as an anxiolytic research compound. Subsequent preclinical research has characterized its activity across GABAergic, monoaminergic, and immune pathway systems, making it a distinctive example of a multi-pathway synthetic peptide (Kolomin et al., 2013).

Structure & Molecular Data

CAS Number	129954-34-3
Molecular Formula	C₃₃H₅₇N₁₁O₉
Molecular Weight	751.87 g/mol
Amino Acid Count / Structure	7-amino-acid synthetic heptapeptide
PubChem CID	11765649
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Appearance	Lyophilized white powder
Storage	Store at -20°C. Protect from moisture.
Solubility	Soluble in sterile water and bacteriostatic water

 

Compound Class & Mechanism

Selank has been reported to modulate GABAergic signaling in preclinical anxiety research models, with documented effects on benzodiazepine binding sites and downstream GABA-A receptor function. Unlike benzodiazepine compounds, Selank activity appears to occur without classical sedative-hypnotic profiles in experimental settings.

Research has also characterized Selank effects on monoaminergic neurotransmitter systems including serotonin and dopamine, as well as modulation of brain-derived neurotrophic factor (BDNF) expression in preclinical models. The compound’s tuftsin-derived structure additionally contributes to research documenting its effects on macrophage and natural killer cell activity (Semenova et al., 2007).

Research Findings

Selank has been investigated in preclinical research spanning anxiolytic pathway studies, cognitive research models, and immunomodulatory pathway research. Published research has documented findings in the following domains:

Key Research Areas

• Anxiolytic Pathway Research: GABAergic modulation in preclinical anxiety models
• Cognitive Research: BDNF expression, memory-associated pathway studies
• Monoaminergic Systems: serotonin and dopamine pathway modulation research
• Immune System Research: tuftsin-derived immunomodulatory activity

Collectively, Selank research has established the compound as a distinctive research reference peptide at the intersection of CNS pathway research and immunomodulatory biology (Kolomin et al., 2013).

Research Context

Researchers study Selank to investigate the intersection of peptide-based anxiolytic pathways and immune system signaling. Its activity across both CNS and peripheral immune systems makes it a distinctive research tool compared to single-pathway compounds.

References

Zozulya AA. et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic drug Selank in the therapy of generalized anxiety disorders. Human Psychopharmacology. PMID: 18622260

Kolomin T. et al. (2013). The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Molecular Immunology.

Semenova TP. et al. (2007). Effects of heptapeptide Selank on learning and memory in rats. Bulletin of Experimental Biology and Medicine.

Kozlovskii II. et al. (2006). The effect of heptapeptide Selank on the monoaminergic systems of the rat brain. Neuroscience and Behavioral Physiology.

Uchakina ON. et al. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova.

Sollertinskaya TN. et al. (2009). Compensatory effects of heptapeptide Selank on conditioned reflex and memory function in Macaca rhesus monkeys. Journal of Evolutionary Biochemistry and Physiology.

 

REGULATORY & LEGAL NOTICE Intended Use. This product is sold exclusively as a research chemical for use in controlled laboratory settings by qualified scientific professionals. It is intended solely for in vitro research, analytical standards, and non-clinical preclinical experimentation. The product is not a drug, dietary supplement, cosmetic, food product, or consumer article of any kind. Prohibited Uses. This product is NOT for use in humans, NOT for veterinary use, NOT for in vivo use in any species, NOT for diagnostic use, NOT for therapeutic use, NOT for food or agricultural use, and NOT for compounding into any preparation intended for administration to humans or animals. Qualified Professionals Only. Purchasers represent that they are qualified scientific professionals, licensed researchers, or authorized personnel at a research institution, and that this product will be handled in accordance with all applicable institutional, federal, state, and local regulations governing research chemicals. Regulatory Notice. The statements made regarding this product have not been evaluated by the U.S. Food and Drug Administration. This product has not been approved by the FDA for any therapeutic, diagnostic, or preventive use. Not a Compounding or Outsourcing Facility. Sirius Molecules is a research chemical supplier. Sirius Molecules is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Legal Compliance. Purchasers are solely responsible for ensuring that their acquisition, possession, handling, and use of this product complies with all applicable laws and regulations in their jurisdiction.